A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer

European Journal of Cancer

Volumn 47, Issue 14, 2011, Pages 2091-2098

  Amadori, D ^a   Milandri, C ^a   Comella, G ^b   Saracchini, S ^c   Salvagni, S ^d   Barone, C ^e   Bordonaro, R ^f   Gebbia, V ^g   Barbato, A ^h   Serra, P ^a   Gattuso, D ⁱ   Nanni, O ^a   Baconnet, B ^h   Gasparini, G ⁱ  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f ARNAS Garibaldi   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

^h Cephalon   (France)

ⁱ SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Metastatic breast cancer; Non pegylated liposomal doxorubicin; Phase I II trial

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CIRCADIAN RHYTHM; CONSCIOUSNESS; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEVER; GRANULOCYTOPENIA; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; METASTASIS; MOUTH DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; ORAL TOXICITY; PAIN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE; HUMANS; LIPOSOMES; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME;

EID: 80052516749     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.05.005     Document Type: Article

References (26)

1. R. Fossati, C. Confalonieri, and V. Torri Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women J Clin Oncol 16 1998 3439 3460 (Pubitemid 28481644)
2. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
3. M. Marty, F. Cognetti, and D. Maraninchi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 2005 4265 4274 (Pubitemid 46207001)
4. K.S. Pawan, and N. Iliskovic Doxorubicin-induced cardiomyopathy N Engl J Med 339 1998 900 905 (Pubitemid 28446849)
5. G. Minotti, A. Saponiero, and S. Licata Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium Clin Cancer Res 7 2001 1511 1515 (Pubitemid 32708613)
6. I. Smith, M. Procter, and R.D. Gelber 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial Lancet 369 2007 29 36 (Pubitemid 46039831)
7. M.E. O'Brien, N. Wigler, and M. Inbar Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann Oncol 15 2004 440 449 (Pubitemid 38444547)
8. L. Harris, G. Batist, and R. Belt Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma Cancer 94 2002 25 36 (Pubitemid 34049039)
9. M. Marty, V. Laurence, and P. Cottu A phase I dose escalation study of non-pegylated liposomal doxorubicin (M) and docetaxel (D) in patients (pts) with previously untreated advanced breast cancer Ann Oncol 13 Suppl. 5 2002 55 [abstract 196P]
10. J. Trigo, M.A. Climent, and A. Lluch Liposomal doxorubicin Myocet® in combination with Herceptin® and paclitaxel is active and well tolerated in patients with HER2-positive locally advanced or metastatic breast cancer: a phase II study Breast Cancer Res Treat 82 Suppl. 1 2003 S83 [abstract 351]
11. J. Cortes, S. Di Cosimo, and M.A. Climent Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/I study Clin Cancer Res 15 2009 307 314
12. F. Lavelle, M.C. Bissery, and C. Combeau Preclinical evaluation of docetaxel (Taxotere) Semin Oncol 22 Suppl. 4 1995 3 16
13. A.-R. Hanauske, D. Degen, S.G. Hilsenbeck, M.C. Bissery, and D.D. von Hoff Effects of taxotere and taxol on in vitro colony formation of freshly explanted human tuomor cells Anti-Cancer Drugs 3 1992 121 124
14. J.F. Riou, A. Naudin, and F. Lavelle Effects of taxotere on murine and human tumor cell lines Biochem Biophys Res Commun 187 1992 164 170
15. W. Zoli, A. Flamigni, and G.L. Frassneti In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers Breast Cancer Res Treat 34 1995 63 69
16. S.E. Jones, J. Erban, and B. Overmoyer Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer J Clin Oncol 23 2005 5542 5551
17. J. Tabernero, M.A. Climent, and A. Lluch A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer Ann Oncol 15 2004 1358 1365 (Pubitemid 39295024)
18. K. Bullock, and K. Blackwell Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer Oncologist 13 2008 515 525 (Pubitemid 351872869)
19. P. Khosravi-Shahi, A. Soria Lovelle, and G. Pérez Manga Tumoral angiogenesis and breast cancer Clin Transl Oncol 11 2009 138 142
20. D. Amadori, G.L. Frassineti, and W. Zoli A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer Semin Oncol 23 Suppl. 11 1996 16 22 (Pubitemid 26362180)
21. G.L. Frassineti, W. Zoli, and A. Tienghi The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer Semin Oncol 23 5 Suppl. 12 1996 22 28 (Pubitemid 26391377)
22. R. Paridaens, L. Biganzoli, and P. Bruning Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over J Clin Oncol 18 2000 724 733 (Pubitemid 30106602)
23. S. Chan, K. Friedrichs, and D. Noel Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer J Clin Oncol 17 1999 2341 2354 (Pubitemid 29368232)
24. G.W. Sledge, D. Neuberg, and P. Bernardo Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 2003 588 592 (Pubitemid 46621890)
25. M. Venturini, C. Bighin, and S. Monfardini Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer Breast Cancer Res Treat 95 2006 45 53 (Pubitemid 43228080)
26. M. Venturini, C. Bighin, and F. Puglisi A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer Breast 19 2010 333 338